FAQ on Beam Therapeutics' Presentation of New Sickle Cell Data at EHA2025

What is BEAM-101?

BEAM-101 is an investigational, one-time ex vivo cell therapy developed by Beam Therapeutics, targeting severe vaso-occlusive crises in sickle cell disease by addressing its root cause.

Why is the presentation of BEAM-101 data significant?

The presentation is significant because it showcases updated safety and efficacy outcomes from the BEACON Phase 1/2 trial, offering insights into BEAM-101’s potential as a durable treatment for sickle cell disease.

When and where will the BEAM-101 data be presented?

The data will be presented at the European Hematology Association 2025 Congress in Milan, Italy, from June 12-15, with specific poster sessions on June 13.

How can I learn more about the BEACON Phase 1/2 trial results?

Beam Therapeutics will host a webcast on June 13 at 4:00 p.m. ET to review highlights from the EHA Congress, and the full press release can be viewed at https://ibn.fm/kBIIB.

What makes Beam Therapeutics’ approach to genetic medicine unique?

Beam Therapeutics utilizes base editing, a proprietary technology that enables precise, predictable, and efficient single base changes at targeted genomic sequences without making double-stranded breaks in the DNA, offering a wide range of therapeutic editing strategies.

Where can I find more information about Beam Therapeutics?

For more information about Beam Therapeutics and its research, visit the company’s website at https://beamtx.com/.

What are the implications of BEAM-101 for sickle cell disease patients?

BEAM-101 has the potential to provide a durable treatment by addressing the root cause of sickle cell disease, offering hope for a one-time therapy that could significantly improve patients’ quality of life.

Who is presenting the BEAM-101 data at the EHA2025 Congress?

Beam Therapeutics, a biotechnology firm pioneering precision genetic medicines via base editing, is presenting the updated data from its BEACON Phase 1/2 trial of BEAM-101.